News & Events about Guardant Health Inc.
Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and AnHeart Therapeutics, a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, announced today a strategic collaboration on the development, regulatory approval and...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic to identify advanced or metastatic breast cancer patients with ESR1 mutations who...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is partnering with The Royal Marsden NHS Foundation Trust on Part C of its Tracking mutations in cell free DNA to predict Relapse in eArly Colorectal Cancer (TRACC) study, which will evaluate the use of circulating tumor DNA...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference. Guardant Healths management is scheduled to present and participate in a Q&A session on Monday, January...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Susan G. Komen, the worlds leading breast cancer organization, announced today that they have entered into a partnership to bring the patient perspective to the development of clinical studies that help identify...